Can Alpha Cognition’s new manufacturing process strengthen ZUNVEYL market protection?
Alpha Cognition publishes a ZUNVEYL manufacturing patent application as sales grow, targeting process protection through 2045.
Pharma & Biotech
Pharma & Biotech
Why āshibio’s 40,000-patient ADO2 market estimate requires careful interpretation
āshibio's vantictumab activates bone resorption in 94% of patients. New ADO2 prevalence findings sharpen its clinical and safety questions.
Pharma & Biotech
GC Biopharma expands ALYGLO safety evidence amid growing US immunoglobulin sales
GC Biopharma will present expanded aggregation testing across 18 lots of five IVIG products and a new review of ALYGLO Phase 3 safety data. The analyses identify measurable molecular differences and provide additional safety context, but neither establishes comparative clinical superiority.
Pharma & Biotech
Can āshibio’s andecaliximab stop abnormal bone growth? An 86.2% flare-up reduction raises the stakes
āshibio reports 86.2% fewer FOP flare-ups with andecaliximab in early data, but placebo-controlled evidence remains pending.
Pharma & Biotech
China approves Foresee’s twice-yearly prostate cancer injection. Could it unlock a $123.85m milestone deal?
Foresee's CAMCEVI 42 mg wins China approval for advanced prostate cancer. Examine GeneScience's launch plans, clinical evidence and licensing economics.
Pharma & Biotech
T-MAXIMUM’s off-the-shelf CAR-T shrank brain tumors in early testing. Can Phase 2 confirm the signal?
T-MAXIMUM has received FDA clearance to initiate a Phase 2 study of MT027 in brain metastases from lung and breast cancer. Early results in a small lung cancer cohort support further investigation, but clinical efficacy, neurological safety and manufacturing scalability remain unproven.
Pharma & Biotech
Can Zydus saroglitazar compete with Iqirvo and Livdelzi in the US PBC market?
Zydus saroglitazar shows 60.7% US biochemical response in PBC as its November 27 FDA decision approaches. Examine the Phase 3 evidence.
Pharma & Biotech
What does RC220 dose escalation mean for Racura Oncology’s cancer drug pipeline?
Racura Oncology clears RC220 dose escalation to 100 mg/m² in its lung cancer trial. Examine the safety findings and next clinical milestones.
Pharma & Biotech
Can Lunit’s AI pathology partnership accelerate cancer biomarker discovery?
Lunit will integrate its SCOPE artificial intelligence pathology platform into Discovery Life Sciences' tissue analysis services, expanding access to standardized biomarker research. The collaboration strengthens Lunit's precision oncology strategy, although financial terms, client adoption and new clinical validation outcomes remain undisclosed.
Pharma & Biotech
Can Chipscreen’s AI-discovered CS43158 overcome leukemia drug resistance? China clears human trials
Chipscreen secures China IND clearance for CS43158, targeting FLT3 mutations and resistance pathways in acute myeloid leukemia.